Is Vertex Pharmaceuticals (VRTX) Still Attractive After Strong Multi Year Share Price Gains

Simply Wall St.02-15

If you are wondering whether Vertex Pharmaceuticals at around US$491.47 is still a sensible entry or hold, the starting point is understanding what you are actually paying for today. The share price ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611144252?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031","is_english":true,"pubTime":"2026-02-15 06:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611144252","market":"hk","top_or_hot":-1,"title":"Is Vertex Pharmaceuticals (VRTX) Still Attractive After Strong Multi Year Share Price Gains","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Vertex Pharmaceuticals at around US$491.47 is still a sensible entry or hold, the starting point is understanding what you are actually paying for today. The share price ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-still-attractive-after-strong\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Vertex Pharmaceuticals (VRTX) Still Attractive After Strong Multi Year Share Price Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Vertex Pharmaceuticals (VRTX) Still Attractive After Strong Multi Year Share Price Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-15 06:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-still-attractive-after-strong><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Vertex Pharmaceuticals at around US$491.47 is still a sensible entry or hold, the starting point is understanding what you are actually paying for today. The share price ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-still-attractive-after-strong\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0256863811.USD","symbol_name":"ALLIANZ US EQUITY \"A\" INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-still-attractive-after-strong","article_id":"2611144252","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-vertex-pharmaceuticals-vrtx-still-attractive-after-strong","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611144252","pubTimestamp":1771107396,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Vertex Pharmaceuticals at around US$491.47 is still a sensible entry or hold, the starting point is understanding what you are actually paying for today.\nThe share price has moved 2.8% over the last 7 days, 9.3% over the last 30 days and 8.7% year to date, with a 7.1% return over 1 year, 67.4% over 3 years and 137.4% over 5 years. This naturally raises questions about how much future growth or risk is already reflected in the price.\nRecent coverage has focused on...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","LU0566484027.USD":"安本美国小盘成长股","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","BK4023":"应用软件","VERX":"Vertex, Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","VRTX":"福泰制药","BK4532":"文艺复兴科技持仓","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4567":"ESG概念","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","BK4585":"ETF&股票定投概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4139":"生物科技","LU0079474960.USD":"联博美国增长基金A"},"translate_title":"Vertex Pharmaceuticals(VRTX)在股价多年强劲上涨后仍然具有吸引力吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRTX":1.5,"VERX":1.5,"DCF":1},"content_text":"If you are wondering whether Vertex Pharmaceuticals at around US$491.47 is still a sensible entry or hold, the starting point is understanding what you are actually paying for today. The share price has moved 2.8% over the last 7 days, 9.3% over the last 30 days and 8.7% year to date, with a 7.1% return over 1 year, 67.4% over 3 years and 137.4% over 5 years. This naturally raises questions about how much future growth or risk is already reflected in the price. Recent coverage has focused on Vertex Pharmaceuticals as a major US biotechnology name, with attention on its portfolio and pipeline developments that often influence how investors think about long term prospects. In addition, broader sector commentary around large biotech companies has kept Vertex in the conversation for investors comparing opportunities across healthcare. On Simply Wall St's valuation checks, Vertex Pharmaceuticals scores 3 out of 6, suggesting the stock screens as undervalued on some methods while looking more fully priced on others. Next we will walk through the key valuation approaches behind that score and finish with a way to frame valuation that goes beyond any single model.  Find out why Vertex Pharmaceuticals's 7.1% return over the last year is lagging behind its peers. AdvertisementApproach 1: Vertex Pharmaceuticals Discounted Cash Flow (DCF) Analysis A DCF model projects a company’s future cash flows and then discounts them back to today’s value to estimate what the business might be worth right now. For Vertex Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on free cash flow in $. The latest twelve month free cash flow sits at about $3.32b. Analysts provide explicit forecasts for the next few years, and Simply Wall St extends these to a 10 year path, with projected free cash flow of $7.66b in 2030. Each of those future cash flows is discounted back to today using a required rate of return to account for risk and the time value of money. On this basis, the estimated intrinsic value from the DCF is about $767.46 per share, compared with the current share price of around $491.47. That gap implies the shares trade at roughly a 36.0% discount to this cash flow based estimate. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Vertex Pharmaceuticals is undervalued by 36.0%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks. VRTX Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Vertex Pharmaceuticals. Approach 2: Vertex Pharmaceuticals Price vs Earnings For a profitable company like Vertex Pharmaceuticals, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of earnings today. It links directly to what the business is earning right now, so it is often a primary reference point when you are weighing up an entry or hold. What counts as a “normal” P/E really depends on how the market views a company’s growth prospects and risks. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty usually lines up with a lower one. Vertex currently trades on a P/E of about 31.54x, compared with the Biotechs industry average of roughly 22.20x and a peer group average of around 40.87x. Simply Wall St’s Fair Ratio for Vertex, which is its view of an appropriate P/E given factors such as earnings growth, margins, size, industry and risk, is 29.68x. This Fair Ratio goes further than a simple peer or industry comparison because it adjusts for the company’s own characteristics instead of assuming all biotechs should trade on similar multiples. With the actual P/E of 31.54x sitting above the Fair Ratio of 29.68x, the shares screen as somewhat expensive on this metric. Result: OVERVALUED NasdaqGS:VRTX P/E Ratio as at Feb 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 23 top founder-led companies. Upgrade Your Decision Making: Choose your Vertex Pharmaceuticals Narrative Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St you can use Narratives, where you and other investors set out a clear story for Vertex Pharmaceuticals, link that story to explicit assumptions for future revenue, earnings and margins, and end up with a fair value that can be compared with today’s price. This all takes place within an easy Community tool that updates automatically when new earnings or news arrive. You can then see, for example, how one Narrative might point to a fair value closer to the more cautious targets around US$330 to US$344, while another points toward the upper end near US$604 to US$624. From there you can decide for yourself whether the current share price of about US$491.47 looks high, low or roughly in line with the scenario you find most convincing. For Vertex Pharmaceuticals, we will make it really easy for you with previews of two leading Vertex Pharmaceuticals Narratives: 🐂 Vertex Pharmaceuticals Bull Case Fair value: about US$504.04 per share Current price vs this fair value: around 2.5% below that estimate Implied revenue growth used in this view: about 9.6% a year  Focuses on expanding cystic fibrosis therapies and new launches like ALYFTREK, CASGEVY and JOURNAVX to support sustained revenue and margin growth. Assumes broader adoption of genomic and gene editing treatments, plus rising global healthcare spending, will support a larger addressable market for Vertex over time. Still flags key risks around CF concentration, R&D spend, pricing pressure and regulatory or competitive setbacks that could weigh on profitability.  🐻 Vertex Pharmaceuticals Bear Case Fair value: about US$377.52 per share Current price vs this fair value: around 30.1% above that estimate Implied revenue growth used in this view: about 2.6% a year  Highlights pressure from drug pricing reforms, high treatment costs and tighter reimbursement as potential headwinds for revenue growth and margins. Sees heavy R&D demands, concentrated rare disease exposure and rising competition as sources of earnings volatility and market share risk. Assumes the current share price already reflects high expectations for gene editing and other late stage programs, leaving less room if execution or data disappoints.  If you want to go beyond these quick previews and see which set of assumptions lines up with your own view on growth, risk and valuation, Curious how numbers become stories that shape markets? Explore Community Narratives. Do you think there's more to the story for Vertex Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGS:VRTX 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611144252","isCrawlerRequest":true}